Skip to main content

Table 3 Correlations between the clinicopathological factors and estrogen receptors (ERa, ERb)

From: GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

Variables Expression of ERα p value Expression of ERβ p value
  Positive Negative   Positive Negative  
Age 55.9 ±13.1 52.6±13.1 0.12 55.8 ±12.3 53.6±11.9 0.37
 Premenopausal 24 (36.4%) 42 (63.6%) 0.24 16 (24.2%) 50 (75.8%) 0.85
 Postmenopausal 41 (42.7%) 55 (57.3%)   20 (20.8%) 76 (79.2%)  
BMI 22.3 ±2.5 21.7 ±2.6 0.24 21.7 ± 4.5 22.0 ± 2.9 0.75
Borderline malignancy 5 (50.0%) 5 (50.0%) 0.72 6 (60.0%) 4 (40.0%) 0.08
FIGO stage I 10 (25.6%) 29 (74.4%) 0.99 14 (35.9%) 25 (64.1%) 0.06
     II 9 (64.3%) 5 (35.7%)   2 (14.3 %) 12 (85.7%)  
     III 34 (44.2%) 43 (55.8%)   14 (18.2%) 63 (81.8%)  
     IV 7 (31.8%) 15 (68.2%)   0 (0%) 22 (100%)  
Histology       
 Borderline malignancy 5 (50.0%) 5 (50.0%) 0.72 6 (60.0%) 4 (40.0%) 0.08
 Serous adenocarcinoma 32 (52.5%) 29 (47.5%) 0.004 11 (18.0%) 50 (82.0%) 0.14
 Endometrioid adenocarcinoma 16 (53.3%) 14 (46.7%)   4 (13.8%) 26 (86.2%)  
 Mucinous adenocarcinoma 5 (26.3%) 14 (73.7%)   8 (42.1%) 11 (57.9%)  
 Clear cell adenocarcinoma 3 (10.3%) 26 (89.7%)   6 (20.7%) 23 (79.3%)  
 Others 4 (30.8%) 9 (69.2%)   1 (7.7%) 12 (92.3%)  
Recurrence    0.14    0.06
 ≤ 6M 8 (42.1%) 11 (57.9%)   4 (21.1%) 15 (78.9%)  
 > 6M 31 (48.4%) 33 (51.6%)   10 (15.6%) 54 (84.4%)  
 No recurrence 26 (32.9%) 53 (67.1%)   22 (27.8%) 57 (72.2%)  
5-year survival    0.47    0.06
 Alive 41 (40.2%) 61 (59.8%)   26 (25.4%) 76 (74.6%)  
 Dead 24 (40.0%) 36 (60.0%)   10 (16.7%) 50 (83.3%)